G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 958.4 INR -3.57% Market Closed
Market Cap: 117.4B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Gross Margin
Glenmark Life Sciences Ltd

54.9%
Current
53%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.9%
=
Gross Profit
12.1B
/
Revenue
22B

Gross Margin Across Competitors

Country IN
Market Cap 117.4B INR
Gross Margin
55%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.1B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 348B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.1B USD
Gross Margin
71%
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
117.4B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd., a spin-off from the parent company Glenmark Pharmaceuticals, has carved out its niche in the competitive world of active pharmaceutical ingredients (APIs). This Mumbai-based entity emerged as an independent public company, growing its presence in both the domestic and international markets. Glenmark Life Sciences strategically focuses on the manufacture and supply of high-quality APIs used across a diverse range of therapeutic areas including cardiovascular, central nervous system disorders, diabetes, pain management, and oncology. By maintaining a robust portfolio of over 120 APIs, the company ensures its penetration in the growing pharmaceutical sector, which increasingly demands reliable and efficient raw materials for drug production. Through its four state-of-the-art manufacturing facilities, Glenmark Life Sciences capitalizes on its well-established research and development capabilities to enhance its manufacturing processes and expand its product range. The company's business model is meticulously designed around long-term relationships with major pharmaceutical players, fostering partnerships that drive consistent revenue streams. By leveraging cost-effective manufacturing practices and an expansive distribution network across major pharmaceutical markets, Glenmark Life Sciences not only optimizes its production capabilities but also ensures timely delivery and high-quality standards. The company's success rests on its ability to balance operational efficiency with strategic expansion into high-growth markets, reinforcing its reputation as a reliable API supplier in the global pharmaceutical industry.

GLS Intrinsic Value
729.79 INR
Overvaluation 24%
Intrinsic Value
Price
G

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.9%
=
Gross Profit
12.1B
/
Revenue
22B
What is the Gross Margin of Glenmark Life Sciences Ltd?

Based on Glenmark Life Sciences Ltd's most recent financial statements, the company has Gross Margin of 54.9%.